Breast cancer gene test could spare some women chemo

A test that measures gene activity can help tailor treatment for some women with early-stage breast cancer, according to a clinical trial. Scientists used the Oncotype Dx test to predict how likely hormone receptor-positive breast cancer was to come back after surgery. Hormone therapy alone was as good as a combination of chemotherapy and hormone therapy in women with an intermediate risk of their cancer returning. This would mean those women can be spared chemotherapy, and its associated side effects, after surgery. Scientists previously found that women with a low risk of their cancer returning can receive hormone therapy alone. And